

AMENDMENTS TO THE SPECIFICATION:

Please replace the 1st paragraph of page 1, as amended in the response filed on October 23, 2001, with the following rewritten paragraph:

This application is a ~~continuation-in-part of International Application No. PCT/IB96/00461, filed May 15, 1996;~~ a continuation-in-part of U.S. Serial No. 08/913,290, a U.S. national stage application of International Application No. PCT/IB96/00461, filed under 35 U.S.C. § 371 on March 20, 1998, now U.S. Pat. No. 6,241,985 ~~filed May 15, 1996;~~ a continuation-in-part of U.S. Serial No. 08/877,511, filed June 17, 1997, ~~now U.S. Pat. No. 6,086,873, which is a continuation-in-part of International Application No. PCT/IB96/00461, filed May 15, 1996, now WO 97/42973 A1;~~ and a continuation-in-part of U.S. Serial No. 09/094,598, filed June 15, 1998, ~~now abandoned, which is a continuation-in-part of U.S. Serial No. 08/877,511, filed June 17, 1997, now U.S. Pat. No. 6,086,873, which is a continuation-in-part of International Application No. PCT/IB96/00461, filed May 15, 1996, now WO 97/42973 A1.~~ U.S. Serial No. 09/094,598 is also a continuation-in-part of PCT/IB96/00461.

Please replace the 2nd full paragraph of page 25 with the following rewritten paragraph:

In an embodiment of the invention, a suitable composition for the treatment of an ovarian tumor associated antigen contains a binding agent that binds the CA 125 antigen. Exemplary binding agents that bind to CA 125 include antibody B43.13 produced by the mouse hybridoma B43.13 (MCB-ALT-96), which was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, on May 18, 2000, and was given ATCC deposit number PTA-1883. In another embodiment of the invention, a suitable composition for the treatment of gastrointestinal cancer contains a binding agent that binds the CA 19.9 antigen. In yet another embodiment of the invention, a suitable composition for the treatment of breast cancer contains a binding agent that binds the CA 15.3 antigen. Various binding agents, antibodies, antigens, and methods for preparing, isolating, and using the antibodies are described in U.S. Patent 4,471,057 (Koprowski) and U.S. Patent 5,075,218

(Jette, et al.), both incorporated herein by reference. Furthermore, many of these antibodies are commercially available from Centocor, Abbott Laboratories, Commissariat a L'Energie Atomique, Hoffman-LaRoche, Inc., Sorin Biomedica, and FujiRebio.